You are viewing the site in preview mode

Skip to main content

Advertisement

Table 3 Diagnostic performance of five non-invasive tests for determining significant fibrosis (METAVIR F ≥ 2)

From: Novel serum biomarkers modified by the body mass index z-score for the detection of liver fibrosis and steatosis in children with chronic hepatitis C

Significant fibrosis (METAVIR F ≥ 2)
Test APRI M-APRI FIB-4 M-FIB-4 B-AST
AUROC (95% CI) 0.752 (0.561–0.890) 0.842 (0.663–0.948) 0.708 (0.514–0.859) 0.823 (0.641–0.937) 0.848 (0.670–0.952)
Cut-off 0.656 0.577 0.180 0.179 92.82
Sensitivity (95% CI) 57.1 (18.4–90.1) 71.4 (29.0–96.3) 85.7 (42.1–99.6) 71.4 (0.29–96.3) 71.4 (0.29–96.3)
Specificity (95% CI) 91.3 (72.0–98.9) 95.6 (78.1–99.9) 65.2 (42.7–83.6) 91.30 (72.0–98.9) 95.7 (78.1–99.0)
+ PV 66.7 (31.5–89.7) 83.3 (41.0–97.3) 42.9 (28.4–58.6) 71.4 (38.0–91.1) 83.3 (41.0–97.3)
- PV 87.5 (74.7–94.3) 91.7 (77.3–97.3) 93.7 (70.5–99.0) 91.3 (76.4–97.2) 91.7 (77.3–97.3)
  1. APRI aspartate-to-platelet ratio index, FIB-4 Fibrosis-4 index, M-APRI modified aspartate-to-platelet ratio index (BMI z-score x APRI), M-FIB-4 modified Fibrosis-4 index (BMI z-score x FIB-4), B-AST BMI z-score x AST, AUROC area under the receiver operating characteristic, 95% CI 95% confidence interval, + PV positive predictive value, − PV negative predictive value